

---

**b. OMI raw data**

OMC-BUS-3/4 Amendment 4

Table 4.1  
Oral Busulfan Pharmacokinetic Parameters

Patient ID	Dose (mg)	Tlag (hr)	Cmax (ng/mL)	Tmax (hr)	T1/2 (hr)	AUClast (uMol-min)	AUCinf (uMol-min)	AUCext (%)	CL/F (mL/min)	Vz/F (L)	CL/F/ABW (mL/min/kg)	Vz/F/ABW (L/kg)	Abs F (%)
N	9.0	9.00	9	9.00	9.00	9	9	9	9.00	9.00	9.00	9.00	9
Mean	63.9	0.22	870	2.76	3.55	790	1396	41	194.73	57.62	2.50	0.73	96
Median	64.0	0.25	728	2.07	3.17	777	1356	36	176.15	53.65	2.73	0.73	92
SD	7.2	0.23	260	1.26	1.17	137	334	14	52.03	15.64	0.45	0.13	12
CV	11.2	105.19	30	45.69	33.06	17	24	34	26.72	27.15	18.18	17.07	12
Maximum													
Minimum													

\* Patient Not Included in Summary

## OMC-BUS-3/4 Amendment 4

Table 4.2  
Intravenous Busulfan Pharmacokinetic Parameters

Patient ID	Dose (mg)	Cmax (ng/mL)	Tmax (hr)	T1/2 (hr)	AUCss (uMol·min)	CL (mL/min)	Vz (L)	CL/ABW (mL/min/kg)	Vz/ABW (L/kg)
N	9.0	9	9.00	9.00	9	9.00	9.00	9.00	9.00
Mean	51.2	1167	1.99	3.11	1156	182.34	48.77	2.36	0.64
Median	50.6	1127	1.92	3.17	1178	181.29	49.54	2.37	0.62
SD	5.6	141	0.20	0.32	158	29.59	7.40	0.31	0.11
CV	10.9	12	9.83	10.41	14	16.23	15.17	12.92	17.04
Maximum									
Minimum									

\* Patient Not Included in Summary

OMC-BUS-3

Table 8  
 Summary of Intravenous Busulfan Pharmacokinetic Parameters from Dose 1 (BMT Day -7)

Dose (mg)	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (hr)	T <sub>1/2</sub> (hr)	AUC <sub>last</sub> (uMol-min)	AUC <sub>Inf</sub> (uMol-min)	AUC <sub>ext</sub> (%)	CL (mL/min)	V <sub>Z</sub> (L)	CL/ABW (mL/min/kg)	V <sub>Z</sub> /ABW (L/kg)
39.00	39	39.00	39.00	39	39	39	39.00	39.00	39.00	39.00
53.23	890	2.09	3.20	757	1194	33	188.52	50.66	2.37	0.62
53.00	910	1.92	2.96	765	1188	34	181.44	49.35	2.33	0.60
9.87	185	0.47	1.06	148	324	9	42.44	13.28	0.61	0.11
18.55	21	22.69	33.10	20	27	25	22.51	26.21	25.67	17.78
N										
Mean										
Median										
SD										
CV										
Maximum										
Minimum										

---

**c. Literature Studies**

## Busulfan Bioavailability

By Moustapha Hassan, Per Ljungman, Per Bolme, Olle Ringdén, Zuzana Syručková, Albert Békássy, Jan Starý, Inger Wallin, and Nils Källberg

Busulfan is widely used as a component of the myeloablative therapy in bone marrow transplantation. Recent studies have shown that the drug disposition is altered in children and is associated with less therapeutic effectiveness, lower toxicities, and higher rates of engraftment failure. We have evaluated the bioavailability of the drug in two groups of patients: eight children between 1.5 and 6 years of age and eight older children and adults between 13 and 60 years. Oral bioavailability showed a large interindividual variation. In children, the bioavailability ranged from 0.22 to 1.20, and for adults, it was within the range 0.47 to 1.03. The elimination half-life after intravenous administration in children ( $2.46 \pm 0.27$  hours; mean  $\pm$  SD) did not differ from that obtained for adults ( $2.61 \pm 0.62$  hours). However, busulfan

clearance normalized to body weight was significantly higher in children ( $3.62 \pm 0.78$  mL $\cdot$ min $^{-1}\cdot$ kg $^{-1}$ ) than that in adults ( $2.49 \pm 0.52$  mL $\cdot$ min $^{-1}\cdot$ kg $^{-1}$ ). Also, the distribution volume normalized for body weight was significantly higher in children ( $0.74 \pm 0.10$  L $\cdot$ kg $^{-1}$ ) compared with  $0.56 \pm 0.10$  L $\cdot$ kg $^{-1}$  in adults. The difference in clearance between children and adults was not statistically significant when normalized to body surface area, which most probably shows that busulfan dosage should be calculated on the basis of surface area rather than body weight. However, to avoid drug-related toxicities, drug monitoring and an individual dose adjustment should be considered because of the variability in busulfan bioavailability.

© 1994 by The American Society of Hematology.

**B**ONE MARROW transplantation (BMT) using busulfan and cyclophosphamide (BUCY) as myeloablative regimen has become a widespread treatment in hematologic malignancies<sup>1,2</sup> and nonmalignant disorders such as immunodeficiencies, thalassemia, and osteopetrosis.<sup>3-5</sup> Busulfan has been introduced as an alternative for total body irradiation (TBI). The therapeutic efficacy for BUCY is considered to be equivalent if not superior to cyclophosphamide and TBI<sup>6</sup> and the busulfan dose was established to 1 mg/kg every 6 hours for 16 doses. However, a randomized French study in patients with acute myeloid leukemia showed a survival advantage for patients treated with TBI<sup>7</sup> and a Nordic multicenter trial found an increased transplant-related mortality associated with busulfan treatment.<sup>8</sup>

Busulfan's pharmacokinetics has been extensively studied during the last years in both adults and children.<sup>9-14</sup> In children, lower plasma levels of busulfan, minimal toxicity and higher rates of failure to achieve engraftment have been reported.<sup>10-14</sup>

These studies showed an alteration in busulfan disposition in children compared with adults. Despite the long clinical use of busulfan, and because of the fact that there is no parenteral drug available, the influence of bioavailability on the blood level could not be studied. We conducted this investigation to study the bioavailability of busulfan in children and adult patients.

From the Karolinska Pharmacy, Research Department and Departments of Medicine, Pediatrics, and Immunology, Huddinge Hospital, Stockholm, Sweden; Department of Pediatrics II, FN Almal, Prague, Czechoslovakia; and the Department of Pediatrics, University Hospital, Lund, Sweden.

Submitted October 4, 1993; accepted June 2, 1994.

Supported by Grant No. 2805-B91-02XAA from the Swedish Cancer Society.

Address reprint requests to Moustapha Hassan, PhD, Karolinska Pharmacy, PO Box 160, S-171 76 Stockholm, Sweden.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1994 by The American Society of Hematology.  
0006-4971/94/07-00195\$3.00/0

### MATERIALS AND METHODS

**Patients.** Eight children with median age of 1.5 years and eight adults (seven adults and one older child with median age 43 years) undergoing BMT took part in the study (Table 1). Patients were hospitalized 2 days before their high-dose therapy. All patients had a normal liver function immediately before entering the study and none of the patients were given other medications during the period of the study. The first day, 1.0 mL was given as a bolus injection (0.5 minutes) of about 2 mg busulfan (Table 1). The injection solution was prepared by dissolving busulfan powder, for human use (Wellcome Foundation Ltd, Beckenham, UK) in 2 mL (propyl)-ne glycol, ethanol, dimethyl sulfoxide (DMSO): 0.8, 0.50, and 0.70 mL, respectively. The solution was passed through a Millex filter (0.22  $\mu$ m, Millipore CV, Bedford, MA) and was examined and found to be pyrogen free and sterile. Busulfan solution was prepared, analyzed for each individual, and kept at 4°C for no more than 12 hours before administration because of the poor stability of busulfan in this formulation ( $t_{1/2} = 114$  hours at 20°C). On the second day, a 2-mg tablet (Wellcome) was administered. All the patients received their oral dose from the same batch, where the tablets were assayed for busulfan concentration ( $2.00 \pm 0.04$  mg/tablet,  $n = 5$ ). The drug was administered at 8 AM, on both first and second day, to minimize the risk of chronopharmacologic variation described previously.<sup>12,13</sup> High-dose therapy with busulfan was started (1 mg/kg every 6 hours for 16 doses) on the third day. The study was designed according to the recommendations of the ethics committee at the Karolinska Institute and was approved by the Swedish Medical Products Agency. The adult patients and the parents for the younger patients were informed and asked for their consent.

**Samples.** Whole blood samples (1 to 2 mL for children and 2 to 5 mL for adults) were obtained from indwelling venous catheters before the drug administration and at 2.5, 5, 10, 20, 30, 60, 75, 90, 120, 150, 240, 300, 360, 450, and 600 minutes after the dose. Blood samples were also obtained from the patients during high-dose therapy immediately before each dosage interval to determine the mean minimum concentrations of the drug, except for three adult patients (LA, LA, and BN) because they have been conditioned with TBI. Plasma was separated and frozen at -20°C until assay.

**Drug analysis.** Busulfan concentrations in plasma were measured using gas chromatography with electron capture detection as described previously.<sup>15</sup>

**Pharmacokinetics.** Individual pharmacokinetic parameters for oral administration curves were evaluated and fit by a one-compartment model with first-order absorption. The intravenous administration curves were evaluated using a two-compartment model. Parameter estimation using nonlinear least squares analysis was performed

Table 1. Clinical Data for All Patients

Patient	Sex	Weight (kg)	Length (cm)	Age (yr)	Diagnosis	SA (m <sup>2</sup> )	Dose (mg)
LS	F	10.4	86	1.5/12	ALL	0.52	3.03
MH	M	10.5	78	2	Hurler	0.49	1.97
JJ	F	12.8	97.5	3.4/12	AML	0.61	1.94
EO	M	19.0	103	3.7/12	AA	0.77	2.00
CH	F	20.0	100	3.6/12	FHL	0.78	1.92
DM	M	14.5	98	5	B-DA	0.65	2.10
MW	F	18.5	113	6	AML	0.78	1.84
MS	F	20	116	6	AML	0.83	1.72
MM	M	38.4	154	13	AML	1.30	1.91
LM	M	68	179	20	AML	1.84	2.00
YN	F	55	174	34	AML	1.64	2.13
SO	M	70	184	43	AML	1.89	1.54
LA	M	74	173	49	CML	1.88	2.00
BN	F	69	176	50	ALL	1.84	2.00
RS	M	95	176	60	AML	2.13	1.64
UA	M	89	185	48	Myeloma	2.23	1.97

Dose values represent the exact dose injected intravenously into each patient.

Abbreviations: AML, acute myelocytic leukemia; AA, aplastic anemia; FHL, familial erythrophagocytic lymphohistiocytosis; B-DA, Blackfan-Diamond anemia.

using PCNONLIN (Statistical Consultants, Lexington, KY) and the estimation curves to high-dose concentration data were performed using SIPHAR (Smid, Paris, France).

Kinetic parameters estimated using PCNONLIN are absorption constant ( $k_a$ ), elimination constant ( $k_e$ ), distribution volume at steady-state level ( $V_{dss}$ ), lag time, and area under the curve (AUC).

The differences in pharmacokinetic parameters between the groups were compared using the Student's *t*-test. The correlation between the pharmacokinetic parameters and age was established using a linear regression method.

The absolute bioavailability was obtained by comparing AUCs for intravenous and oral administration for each individual.

## RESULTS

The plasma concentration curves for two patients (LS and EO) after oral and intravenous administration of busulfan are given in Figs 1 and 2.

Table 2 shows the calculated pharmacokinetic parameters

for both adults and children after intravenous administration of the drug. Clearance normalized for body weight was significantly ( $P = .004$ ) higher in children with a value of  $3.62 \pm 0.78 \text{ mL} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$  (mean  $\pm$  SD) compared with adult patients ( $2.49 \pm 0.52 \text{ mL} \cdot \text{min}^{-1} \cdot \text{kg}^{-1}$ ). An age-related clearance was shown (Fig 3) by a regression analysis ( $P = .02$ ). However, this difference was not significant when clearance was normalized to surface area (Table 2).

The distribution half-lives ( $\alpha$ ) in both children and adults were similar (0.059 and 0.051 hours, respectively). Also, the elimination half-lives ( $\beta$ ) for children ( $2.46 \pm 0.27$  hours) did not differ from those for adults ( $2.61 \pm 0.62$  hours). The estimated  $V_{dss}$  was  $0.74 \pm 0.10 \text{ L} \cdot \text{kg}^{-1}$  for the children, which was significantly higher ( $P < .005$ ) than that estimated for the adult patients ( $0.56 \pm 0.10 \text{ L} \cdot \text{kg}^{-1}$ ). The AUCs for children ranged from 309 to  $1.510 \text{ ng} \cdot \text{hr} \cdot \text{mL}^{-1}$ , whereas for adults, the values were within the range 103 to  $270 \text{ ng} \cdot \text{h}$ .




Fig 1. Plasma time-concentration curve after 3.03 mg intravenous (●) and 2 mg oral administration (▲) of busulfan (patient LS with bioavailability of 52%).




Fig 2. Plasma time-concentration curve after 2 mg intravenous (●) and 2 mg oral administration (▲) of busulfan (patient EO with 100% bioavailability).

Table 2. Pharmacokinetic Parameters for Intravenous Administration

Patient	$\alpha$ (h)	$\beta$ (h)	$V_{dss}$ (L kg <sup>-1</sup> )	$C_{max}$ (mg mL <sup>-1</sup> )	AUC (mg h min <sup>-1</sup> )	Clearance (mL min <sup>-1</sup> kg <sup>-1</sup> )	Clearance (mL min <sup>-1</sup> kg <sup>-1</sup> )
LS	0.027	2.32	0.63	1,308	1,510	64.31	3.22
MH	0.055	2.60	0.87	803	823	81.42	3.99
JJ	0.063	2.66	0.74	439	769	68.93	3.28
EO	0.015	2.65	0.72	294	581	74.51	3.02
CH	0.012	2.61	0.88	753	523	78.44	3.06
DM	0.170	2.71	0.76	296	733	73.46	3.30
MW	0.027	2.05	0.87	751	309	127.24	5.36
MS	0.101	2.04	0.62	292	387	89.25	3.71
MM	0.044	1.98	0.54	458	239	102.46	2.46
LM	0.041	3.08	0.71	121	196	82.43	2.50
YN	0.021	1.88	0.53	750	250	66.59	2.58
SO	0.048	2.16	0.59	139	110	123.28	3.33
LA	0.071	2.73	0.51	179	270	65.67	1.67
BN	0.032	2.81	0.64	104	181	100.08	2.67
RS	0.078	2.70	0.60	77	103	83.66	2.79
UA	0.071	2.52	0.39	181	176	83.66	1.88
Mean for children ( $\pm$ SD)	0.059 (0.054)	2.46 (0.27)	0.74 (0.10)	577 (249)	704 (373)	82.20 (19.73)	3.62 (0.78)
Mean for adults ( $\pm$ SD)	0.051 (0.021)	2.61 (0.62)	0.56 (0.10)	249 (235)	191 (62)	97.25 (19.93)	2.49 (0.52)

Abbreviations:  $\alpha$ , distribution half-life;  $\beta$ , elimination half-life; AUC, area under plasma concentration curve;  $C_{max}$ , maximum plasma concentration;  $V_{dss}$ , distribution volume at steady-state.

mL<sup>-1</sup>. Both the distribution volume and clearance were correlated to age with correlation coefficients of 0.65 and 0.57, respectively (Figs 3 and 4).

The pharmacokinetic parameters, the drug bioavailability after oral administration of 2 mg busulfan and the mean minimum concentrations during high-dose therapy calculated from dose 4 to dose 16 (corrected for 1 mg/kg) are listed in Table 3. The simulated mean minimum concentrations using the obtained parameters ( $k_a$ ,  $k_e$ , and the bioavailability) are also listed in Table 3.

The kinetics of oral busulfan in all patients were fitted to a one-compartment open model with first-order absorption. A large variability was seen in the absorption half-life. In children, the absorption half-life was  $0.37 \pm 0.41$  hours,

whereas in adults, it was  $0.21 \pm 0.21$  hours. No difference in the elimination half-life between children and adults was seen (2.80 and 2.68 hours, respectively). An interindividual variability in the time to reach peak plasma concentration and the area under the concentration time curve was seen. Maximum plasma concentration appeared between 0.29 and 2.75 hours in children and between 0.48 and 2.32 hours in adults. Comparison of AUCs after oral and intravenous administration showed an oral availability of  $0.68 \pm 0.31$  in children and  $0.80 \pm 0.19$  in adults.

#### DISCUSSION

Busulfan pharmacokinetics has been extensively studied in both adults and children during the last few years.<sup>11-15</sup>




Fig 3. The relation between clearance corrected for body-weight and age. The solid line is the regression line and the dotted lines are the 95% confidence interval. Slope =  $-0.023 \pm 0.008$ ,  $r = -.57$ ,  $P = .02$ .




Fig 4. The relation between distribution volume normalized for body-weight and age. The solid line is the regression line and the dashed lines are the 95% confidence interval. Slope =  $-0.004 \pm 0.001$ ,  $r = -.65$ ,  $P = .006$ .

Table 3. Pharmacokinetic Parameters for Per Os Administration

Patient	t <sub>a</sub> (h)	t <sub>e</sub> (h)	T <sub>lag</sub> (h)	T <sub>max</sub> (h)	C <sub>max</sub> (ng mL <sup>-1</sup> )	AUC (ng h mL <sup>-1</sup> )	Bioavailability (%)	High Dose (1 mg/kg)	
								Mean Concentration Found (ng mL <sup>-1</sup> )	Mean Concentration Simulated (ng mL <sup>-1</sup> )
LS	0.08	2.47	0.14	0.54	130	516	52	330 ± 91	297
MH	0.12	3.22	0.02	0.61	28	183	22	160 ± 62	139
JJ	0.08	3.51	0.09	0.54	142	955	120	890 ± 650	810
EO	1.07	2.74	0.42	0.78	86	600	103	583 ± 106	660
CH	0.68	5.03	—	2.38	34	302	55	166 ± 56	176
MW	0.80	1.39	0.70	2.03	53	205	61	319 ± 89	322
DM	0.06	2.32	0.14	0.45	113	414	59	319 ± 69	318
MS	0.05	1.75	0.04	0.29	115	322	72	360 ± 102	365
MM	0.06	2.52	0.18	0.48	66	216	86	300 ± 111	318
LM	0.89	2.41	0.44	2.18	28	159	81	—	—
YN	0.06	1.91	0.43	0.71	41	110	47	310 ± 72	305
SO	0.06	2.01	0.30	0.60	28	89	62	280 ± 60	286
LA	0.31	4.98	0.72	1.50	34	278	103	—	—
BN	0.18	2.73	0.72	2.11	32	180	99	—	—
RS	0.22	2.56	1.46	2.32	19	89	71	677 ± 216	624
UA	0.10	2.25	0.29	0.73	44	168	94	714 ± 85	631
Mean for children (±SD)	0.37 (0.41)	2.80 (1.14)	0.22 (0.25)	1.21 (1.02)	68 (44)	437 (254)	68 (31)	—	—
Mean for adults (±SD)	0.21 (0.21)	2.68 (0.97)	0.56 (0.41)	1.33 (0.78)	37 (14)	161 (66)	80 (19)	—	—

Abbreviations: t<sub>a</sub>, absorption half-life; C<sub>max</sub>, plasma maximum concentration; T<sub>lag</sub>, lag-time; T<sub>max</sub>, time to reach C<sub>max</sub>; t<sub>e</sub>, elimination half-life.

Those studies have shown differences in drug disposition in children compared with adults.

The bioavailability of busulfan was investigated here in eight children and eight adults for the first time since the introduction of the drug in the 1950s.<sup>21</sup> The patients studied showed a high variability in bioavailability of about sixfold in children and twofold in adults. The distribution volumes and the clearance values calculated after an oral dose of 2 mg (with the assumption of complete bioavailability) were in agreement with the previously published data on high-dose therapy (Table 4).

Despite the low administered dose of intravenous busulfan

and with respect to its bioavailability, the levels of busulfan (expressed as a mean minimum concentration) measured during high-dose therapy were in good agreement with those simulated using the pharmacokinetic parameters obtained after oral (2 mg) administration (Table 3). This indicates that our results may also be valid at therapeutic levels and most probably confirms the linear pharmacokinetics of busulfan.

All data from patients receiving oral doses were fitted to a one-compartment open model with first-order absorption.

The younger children showed a slightly, but not significant, slower absorption rate than the adults. This is probably

Table 4. Busulfan Disposition According to Age and Route of Administration

Reference	n	Age (yr)	t <sub>1/2</sub> (h)	Clearance (mL/min/kg) (mean ± SD)	Vd (L/kg) (mean ± SD)
Grochow <sup>22</sup>	28	> 18	2.33	2.9 (1.7)	0.59 (0.44)
Hassan <sup>23</sup>	16	> 18	2.59	2.64 (0.56)	—
Grochow <sup>24</sup>	14	0.2-3.6	1.54	8.4 (4.3)	1.42 (0.83)
Vassal <sup>25</sup>	11	4-14	2.33	4.4 (2.2)	1.06 (0.44)
Vassal <sup>26</sup>	25	2-14	2.94	4.5 (1.4)	1.04 (0.38)
Hassan <sup>27</sup>	9	1.3-14	2.43	4.9 (2.2)	—
Vassal <sup>28</sup>	33	0.2-2.75	2.83	6.8 (3.0)	1.63 (1.29)
Present study					
Oral dose (2 mg) <sup>a</sup>	7†	1.8-6	2.74	5.2 (2.1)	1.15 (0.52)
Oral dose (2 mg) <sup>b</sup>	8	> 13	2.68	3.6 (1.3)	0.64 (0.12)
Intravenous	8	1.8-6	2.46	3.52 (0.78)	0.74 (0.10)
Intravenous	8	> 13	2.61	2.49 (0.52)	0.56 (0.10)

<sup>a</sup> Clearance and distribution volume are calculated with assumption of f = 1 to simplify comparison with published results.

† Patient MH was excluded because of the extreme values of cl (17.3 mL/min/kg) and Vd (11.8 L/kg), which most probably was because of his diagnosis.<sup>21</sup>

caused by differences between adults and children in transit time in the gastric region. In high-dose therapy, the variation can be of a higher magnitude because crushed tablets in combination with gastric tube,<sup>12</sup> in gelatine capsules,<sup>14</sup> and in apple sauce<sup>16</sup> are usually used for younger children. The elimination half-lives were within the range of the average obtained in adults. Only one child showed an extremely long elimination half-life.

According to the venous equilibrium or sinusoidal model,<sup>22</sup> the hepatic clearance of a drug may be increased because of (1) higher metabolic activity as a function of the hepatic mass; (2) decreased plasma protein binding and/or (3) increased hepatic blood flow. On the other hand, the distribution volume may be influenced by body composition, protein binding, and tissue binding of the drug. This study showed potentially important differences between children and adults in the disposition of busulfan. After an intravenous administration of busulfan, both clearance normalized to body weight and distribution volume adjusted to body weight appear to be age dependent (Fig 3 and Fig 4). Clearance and distribution volumes were significantly higher in children than in adult patients (45% and 34%, respectively). No difference in the elimination rate constant was observed. The present results using intravenous busulfan confirm the results reported by several investigators after oral administration of the drug<sup>12-14</sup> regarding busulfan disposition in relation to age (Table 4).

Busulfan protein binding does not explain these differences between adults and children because it was shown that its binding is very low in both high and low doses.<sup>12,13</sup>

In our investigation it was shown that the distribution volume was higher in children than adults. The values obtained after intravenous administration were in agreement with those previously published using oral doses of busulfan<sup>14,16</sup> when the variability in bioavailability was considered. Surprisingly, the values for distribution volumes obtained after intravenous administration corresponded directly to total body water, and the difference between adults and children was equal to that reported for body water.<sup>24,25</sup> This might indicate that despite the lipophilicity of busulfan,<sup>26</sup> it is still distributed to body water. In this respect, busulfan might be like caffeine, which is also a rather lipophilic compound and has a distribution volume equal to body water.<sup>27,28</sup>

The differences in clearance could be explained if the liver blood flow or hepatic mass is different in children compared with adults when normalized to body weight, but not to body surface area. Grygiel et al<sup>29</sup> and Rylance et al<sup>30</sup> showed in two independent studies in children that the liver volume examined by ultrasound scans averaged 30 to 35 mL/kg, whereas in two adult studies,<sup>29,31</sup> the liver volume was 19.5 to 22 mL/kg. Recently, Evans et al<sup>32</sup> showed a clear decrease in liver volume to body weight (mL/kg) with increasing age, but no significant age-related decrease in liver volume was found when correlated with body surface area (mL/m<sup>2</sup>).

Recently, we have shown that [<sup>11</sup>C-busulfan] is highly distributed into the liver of the monkey using positron emission tomography.<sup>33</sup> Grochow et al<sup>34</sup> have suggested the first-pass elimination to explain the high clearance found in children below 4 years of age. Also, it has already been shown

that busulfan is highly metabolized in the liver through enzymatic conjugation with glutathione.<sup>11,34,35</sup> However, to our knowledge, no age-related differences in either glutathione or its transferase in humans have been reported, but it is known that there are a variety of ways in which drug handling in young children may differ from adults,<sup>36,37</sup> and that their metabolic capacity is higher than in adults. It seems clear that children below 6 years of age have a higher hepatic clearance than adults if the adjustment is based on body weight, whereas there is no difference when the surface area is considered.

The elimination half-life for intravenously administered busulfan in young children was longer than that reported previously by Grochow et al and by us using high doses of oral busulfan. However, the elimination values were in better agreement with those reported by Vassal et al.<sup>14</sup> This is most likely a result of an interaction between busulfan and phenytoin used as anticonvulsants in our previous studies.<sup>11,12</sup> Recently, we reported<sup>38</sup> a possible interaction between busulfan and phenytoin, expressed as a lower AUC and faster elimination after the last dose compared with the first dose during high-dose therapy. This interaction or liver activation can be more pronounced in children,<sup>36,37</sup> resulting in a higher hepatic clearance than in adults.

Several investigators have expressed their concern about busulfan dosage in children because of the higher failure rates to achieve engraftment.<sup>16-18</sup> Recently, Vassal et al<sup>39</sup> have recommended a dose of 600 mg/m<sup>2</sup> for young children, whereas Yeager et al<sup>40</sup> have suggested 640 mg/m<sup>2</sup>. In a very recent study, Vassal et al<sup>41</sup> have described a dose of 749 mg/m<sup>2</sup> for children below 3 years of age. The new recommended dosages<sup>39-41</sup> provide systemic drug exposure closer to that obtained in adults. Also, the present results show that a dosage based on the body surface area will be more accurate, might achieve higher therapeutic effectiveness, and will hopefully lower relapse rates in young children. However, Vassal et al<sup>39</sup> reported a higher rate of neurotoxicity using the new dosage, whereas increased incidence of mucositis was reported by Yeager et al.<sup>40</sup> The wide range of AUC observed in both studies can most likely be explained by the variation in bioavailability shown in the present study.

Patient MH in the children's group has shown extremely low bioavailability after oral administration of busulfan (0.22). Vassal et al<sup>41</sup> have recently shown higher clearance and distribution volumes in children with lysosomal storage disease than other children, and a great variation in drug disposition was observed. In fact, this might be caused by low bioavailability of busulfan in children with metabolic disorders disease as observed in the above-mentioned child. Other studies investigating the bioavailability in children with metabolic disorders are urgently warranted.

It has also been shown that some young individuals have very high initial concentrations when busulfan is given as a bolus injection in a dose as low as 3 mg. Indeed, an intravenous formulation is warranted, but not as a bolus form because of the neurotoxicity reported<sup>38,42</sup> and our results showing that at least 20% of the injected dose enters the human brain<sup>33</sup> during the first 5 minutes after administration. Moreover, lack of information about the combined toxicity of

busulfan and DMSO, poor stability of busulfan in the present formulation, and low solubility of busulfan make the injection of higher doses or larger volumes unadvisable.

Our study shows a variability in busulfan bioavailability by fivefold in young children and by twofold in adults. It was also shown that children have significantly higher clearance and distribution volumes compared with adults.

In addition, a dosage regimen based on body surface area might enhance drug efficacy in children,<sup>22-24</sup> but considering the variability in the bioavailability and the correlation between a high systemic exposure to busulfan and both its neurotoxicity<sup>42</sup> and the occurrence of veno-occlusive disease (VOD),<sup>43</sup> therapeutic monitoring of busulfan concentrations and individualized adjustment of its dosage have to be considered to optimize drug exposure and avoid both neurotoxicity and VOD.

#### ACKNOWLEDGMENT

We thank Susanna Kuntien and Victoria Lieu-Wang for invaluable assistance in conducting the present study.

#### REFERENCES

- Santos GW, Tutschka PJ, Broxmeyer H, Saral R, Beschoner WE, Bias WB, Braine HG, Burns WH, Ellenbein GI, Kaizer H, Mellitt D, Sentebrater LL, Stuart RK, Yeager AM: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. *N Engl J Med* 309:1347, 1983
- Nevill TJ, Shepherd JD, Reetz DE, Barnett MJ, Naniel SH, Klingemann H-G, Phillips GL: Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. *Bone Marrow Transplant* 10:443, 1992
- Geller RB, Saral R, Pantadasi S, Zahurak M, Vogelzang GB, Wingard JR, Ambinder RF, Beschoner WB, Braine HG, Burns WH, Hess AD, Jones RJ, May WS, Rowley SD, Wagner JE, Yeager AM, Santos GW: Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. *Blood* 73:2209, 1989
- Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. *Blood* 70:1352, 1987
- Blazar BR, Ramsay NKC, Kersey JH, Krivit W, Arthur DC, Filipovich AH: Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. *Transplantation* 39:597, 1985
- Lucarelli G, Galimberti M, Delfini C, Agostinelli F, Giorgi C, Giardini C, Polchi P, Izzi T, Manna M, Baronciani D, Angelucci E, Polini P, Manenti F: Marrow transplantation for thalassemia following busulfan and cyclophosphamide. *Lancet* 1:1353, 1985
- Parkman R, Rapoport JM, Hollman S, Lipsch J, Smith B, Geha R, Nathan DG: Busulfan and total body irradiation as antiemietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. *Blood* 64:852, 1984
- Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW: Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. *Cancer Treat Rep* 65:711, 1984
- Blaise D, Marinovich D, Archimbaud E, Reiffers J, Derogy A, Jour J, Milpied N, Attal M, Alchabet M, Ibrah N, Keuente M, Duric C, Bourgnai P, Gratcos N, Ruithe F, Guyon D, Gouvernet J, Gluckman E: Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of busulfan versus cytosin versus cytosin-total body irradiation as a preparative regimen: A report from the Group d'Etudes de la Greffe de Moelle Osseuse. *Blood* 79:2678, 1992
- Ringden O, Ruutu T, Remberger M, Nikskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors H, Ljungman P, Mellander L, Jacobsen N: A randomized trial comparing busulfan versus total body irradiation as conditioning in allogeneic marrow transplantation recipient with hematological malignancies. A report from the Nordic Bone Marrow Transplantation Group. *Blood* 83:2723, 1994
- Hassan M, Öberg G, Ehrsson H, Ehrnebo M, Wallin I, Smedmyr B, Tötterman T, Ekshög S, Simonsson B: Pharmacokinetic and metabolic studies of high-dose busulfan in adults. *Eur J Clin Pharmacol* 36:523, 1989
- Hassan M, Öberg G, Belarsky AN, Axhan J, Ehrsson H, Ljungman P, Lännerholm G, Smedmyr B, Taube A, Wallin I, Simonsson B: Pharmacokinetics of high-dose busulfan in relation to age and chromopharmacology. *Cancer Chemother Pharmacol* 28:130, 1991
- Vassal G, Challine D, Kocielny S, Hartmann O, Deroussen A, Bland L, Valteau-Couanet D, Lemerle J, Lévi F, Gouyette A: Chronopharmacology of high-dose busulfan in children. *Cancer Res* 53:1524, 1993
- Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J: Pharmacokinetics of high-dose busulfan in children. *Cancer Chemother Pharmacol* 24:386, 1989
- Grechow LB, Jones RJ, Brundret FE, Braine HG, Chen T-L, Saral R, Santos GW, Colvin OM: Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. *Cancer Chemother Pharmacol* 25:55, 1989
- Grechow LB, Krivit W, Whitley CB, Blazar B: Busulfan disposition in children. *Blood* 75:1722, 1990
- Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJC, Williamson S: Engraftment rates related to busulfan and cyclophosphamide dosages for displacement bone marrow transplant in fifty children. *Bone Marrow Transplant* 1:201, 1986
- Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJC, Barnes R: Busulfan and cyclophosphamide: cause little early toxicity during displacement bone marrow transplantation in fifty children. *Bone Marrow Transplant* 1:193, 1986
- Krivit W, Whitley CB, Chang PN, Belani KG, Snover D, Summers CG, Blazar B: Lysosomal storage diseases treated by bone marrow transplantation: Review of 21 patients. In Johnson L, Pochodly C (eds): *Bone Marrow Transplantation in Children*. New York, NY, Livy, 1990, p261
- Hassan M, Ehrsson H: Gas chromatographic determination of busulfan in plasma with electron-capture detection. *J Chromatogr* 27:374, 1983
- Galton DAG: Myleran in chronic myeloid leukaemia. *Lancet* 1:218, 1971
- Wilkinson GR, Shand DG: A physiological approach to hepatic drug clearance. *Clin Pharmacol Ther* 18:377, 1975
- Ehrsson H, Hassan M: Binding of busulfan to plasma proteins and blood cells. *J Pharm Pharmacol* 36:694, 1984
- Friis-Hansen B: Body water compartments in children. Changes during growth and related changes in body composition. *Pediatrics* 33:169, 1961
- Maxwell GM: Paediatric drug dosing: Bodyweight versus surface area. *Drugs* 37:113, 1989
- Hassan M, Ehrsson H, Wallin I, Ekshög S: Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. *Eur J Drug Metab Pharmacol* 13:201, 1985
- Cheyrol G: Clinical pharmacokinetics of drugs in obesity. An update. *Clin Pharmacol* 25:103, 1993
- Blanchard J, Savers SJA: Comparative pharmacokinetics of

caffeine in young and elderly men. *J Pharmacokinet Biopharm* 11:109, 1983

29. Grygiel JJ, Ward II, Ogborne M, Goldin A, Birken DJ: Relationships between plasma theophylline clearance, liver volume, and body weight in children and adults. *Eur J Clin Pharmacol* 24:529, 1983

30. Rylance GW, Moreland TA, Cowan MD, Clark DC: Liver volume estimation using ultrasound scanning. *Arch Dis Child* 57:243, 1982

31. Roberts CJC, Jackson L, Halliwell M, Branch RA: The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. *Br J Clin Pharmacol* 3:907, 1976

32. Evans WE, Relling MV, De Graaf S, Rodman JH, Pieper JA, Christensen ML, Crom WR: Hepatic drug clearance in children: Studies with indocyanine green as a model substrate. *J Pharm Sci* 78:452, 1989

33. Hassan M, Öberg G, Friszon K, Ehrsson H, Eriksson L, Ingvar M, Stone-Elander S, Thwrell J-O, Smedmyr B, Warne N, Widén L: In vivo distribution of [<sup>14</sup>C]-busulfan in cynomolgus monkey and in the brain of a human patient. *Cancer Chemother Pharmacol* 30:81, 1992

34. Hassan M, Ehrsson H: Metabolism of <sup>14</sup>C-busulfan in isolated perfused rat liver. *Eur J Drug Metab Pharmacokinet* 12:71, 1987

35. Hassan M, Ehrsson H: Urinary metabolites of busulfan in the rat. *Drug Metab Dispos* 15:399, 1987

36. Prandota J: Clinical pharmacokinetics of changes in drug elimination in children. *Dev Pharmacol Ther* 3:311, 1982

37. Morselli PL, Franco-Morselli R, Bossi L: Clinical pharmacokinetics in newborns and infants age-related differences and therapeutic implications. *Clin Pharmacokinet* 5:485, 1980

38. Hassan M, Öberg G, Björkholm M, Wallin I, Lindgren M: Influence of prophylactic anticonvulsant therapy on high-dose busulfan kinetics. *Cancer Chemother Pharmacol* 33:181, 1993

39. Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, Lemerle J, Gouyette A: Is 600 mg/m<sup>2</sup> the appropriate dosage of busulfan in children undergoing bone marrow transplantation? *Blood* 79:2475, 1992

40. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB: Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. *Blood* 80:2425, 1992

41. Vassal G, Fischer A, Challine D, Boland I, Ledwith F, Lemerle S, Vilmer E, Rahiny C, Souillet G, Gluckman E, Michel G, Deroussent A and Gouyette A: Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. *Blood* 82:1030, 1993

42. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, Brugieres L, Kalifa C, Gouyette A, Lemerle J: Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. *Cancer Res* 50:6203, 1990.